Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Similarly, the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) [47] and the Study of Heart and Kidney Protection with Empagliflozin (EMPA-KIDNEY) [48] trials expanded inclusion beyond diabetes mellitus, showing that dapagliflozin and empagliflozin significantly reduced the risk of kidney outcomes, with consistent benefits across a wide range of eGFR and albuminuria
PMID 12818476
It is because of this dual pathway that some clinicians and patients speculate that microdosing may prove effective
Maintenance sessions may be needed
L.LetavernierE.et al (2010)
Request a callback or speak to admissions if you want help choosing between online theory, VTCT study and hands-on training
US$ 25.33
US$ 27.81
US$ 21.60
